Cargando…

Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy

Rosacea is a chronic inflammatory disease with transient and non-transient redness as key characteristics. Brimonidine is a selective α2-adrenergic receptor (AR) agonist approved for persistent facial erythema of rosacea based on significant efficacy and good safety data. The majority of patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Docherty, James R., Steinhoff, Martin, Lorton, Dianne, Detmar, Michael, Schäfer, Gregor, Holmes, Anna, Di Nardo, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083782/ https://www.ncbi.nlm.nih.gov/pubmed/27562835 http://dx.doi.org/10.1007/s12325-016-0404-8

Ejemplares similares

Topical Brimonidine as an Effective Adjuvant to Local Anesthetics for Post Treatment Erythema and Pain Reduction
por: Kwon, Hyun Jung, et al.
Publicado: (2019)

Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
por: Anderson, Michael S, et al.
Publicado: (2017)

In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea
por: Piwnica, David, et al.
Publicado: (2018)

The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea
por: Johnson, Andrew William, et al.
Publicado: (2015)

Topical brimonidine for pyogenic granuloma after paronychia surgery
por: Chen, Yusha, et al.
Publicado: (2020)

The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations
por: Alonso, Ruiz Simonato, et al.
Publicado: (2020)

Potential depressive central nervous system effects of brimonidine topical gel
por: Foschi, Cristina, et al.
Publicado: (2020)

Topical Brimonidine or Intravitreal BDNF, CNTF, or bFGF Protect Cones Against Phototoxicity
por: Valiente-Soriano, Francisco J., et al.
Publicado: (2019)

Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study
por: Orii, Yusuke, et al.
Publicado: (2023)

Effect of Topical Brimonidine 0.15% on Conjunctival Injection after Strabismus Surgery in Children
por: Kim, Dong Hyun, et al.
Publicado: (2021)

Topical Brimonidine Delays Ultraviolet Radiation‐Induced Squamous Cell Carcinoma in Hairless Mice
por: Pinto, Fernanda E., et al.
Publicado: (2022)

Erythema Gyratum Repens Like Figurate Erythema Responding to Topical Steroid in an Healthy Individual
por: Naveen, Kikkeri Narayanasetty, et al.
Publicado: (2013)

Topical brimonidine induced acute uveal effusion in a patient with nanophthalmos: a case report
por: Li, Yakun, et al.
Publicado: (2023)

Erythema Dyschromicum Perstans: Response to Topical Tacrolimus
por: Mahajan, Vikram K, et al.
Publicado: (2015)

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension
por: Gandolfi, Stefano A., et al.
Publicado: (2014)

Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine
por: Tanihara, Hidenobu, et al.
Publicado: (2023)

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study
por: Orii, Yusuke, et al.
Publicado: (2022)

Brimonidine in the treatment of glaucoma and ocular hypertension
por: Cantor, Louis B
Publicado: (2006)

Use of topical brimonidine to prevent intraocular pressure elevations following Nd: YAG-laser posterior capsulotomy
por: Singhal, Deepika, et al.
Publicado: (2011)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
por: Lee, Anne J, et al.
Publicado: (2008)

Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study
por: Layton, A.M., et al.
Publicado: (2015)

The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients
por: Onoe, Hiromitsu, et al.
Publicado: (2022)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
por: Galanopoulos, Anna, et al.
Publicado: (2009)

Salmon patch-like conjunctival lesion secondary to long-term administration of topical brimonidine: A case report
por: Al-Essa, Rakan S., et al.
Publicado: (2023)

Fluorimetric Quantification of Brimonidine Tartrate in Eye Drops
por: Sunitha, G., et al.
Publicado: (2013)

The role of brimonidine tartrate gel in the treatment of rosacea
por: Jackson, J Mark, et al.
Publicado: (2015)

About the pathways to deliver brimonidine to the Muller’s muscle
por: Ghanian, Soha, et al.
Publicado: (2023)

Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs
por: Suzuki, Gen, et al.
Publicado: (2020)

Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage
por: Conti, Federica, et al.
Publicado: (2021)

Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature
por: Konieczka, Katarzyna, et al.
Publicado: (2019)

Brimonidine-associated uveitis – a descriptive case series
por: Hopf, Susanne, et al.
Publicado: (2020)

Preliminary evaluation of the efficacy and safety of brimonidine for general anesthesia
por: Bin, Chen, et al.
Publicado: (2021)

Bilateral Lipid Keratopathy in the Setting of Brimonidine Tartrate Use
por: Moshirfar, Majid, et al.
Publicado: (2023)

Adrenal Disorders and the Paediatric Brain: Pathophysiological Considerations and Clinical Implications
por: Salpietro, Vincenzo, et al.
Publicado: (2014)

Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens
por: Moosavi, Reza, et al.
Publicado: (2018)

Use of brimonidine tartrate to resolve telangiectatic matting: case report
por: de Mello, Brenno Augusto Seabra, et al.
Publicado: (2020)

Intravitreal brimonidine inhibits form-deprivation myopia in guinea pigs
por: Yang, Yifang, et al.
Publicado: (2021)

A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure
por: Hartleben, Curt, et al.
Publicado: (2017)

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
por: Onoe, Hiromitsu, et al.
Publicado: (2021)

Erythema nodosum in an adolescent patient with cryopyrin‐associated periodic syndrome
por: Chan, Linda, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p8mut2dk060371eqi9lii52oho